23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Protagonist Therapeutics, Inc. › 2025-2026

Protagonist Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Protagonist Therapeutics, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 362Asset managers, any item
  • 2,507Fund votes
  • June 17, 2026Meeting date

Results at a glance

Meeting of June 17, 2026: 5 items on Protagonist Therapeutics, Inc.’s Form 8-K, filed June 18, 2026: 3 approved · 2 passed (calculated).

Dissent

Notable dissent: 1 director (13.9% against); 1 equity or compensation plan (15.6% against); 1 other board item (19.8% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Protagonist Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Protagonist Therapeutics, Inc.

These tallies are Protagonist Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Protagonist Therapeutics, Inc. — official shareholder meeting results, meeting held June 17, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Dinesh V. Patel, Ph.D. 48,714,702---- 7,875,3112,819,234 86%Passed (calculated)—
Elect Director: Lewis T. "Rusty" Williams, M.D., Ph.D. 45,371,193---- 11,218,8202,819,234 80%Passed (calculated)—
2. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers 53,412,5593,164,70212,752 --2,819,234 94%Approved—
3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026 59,371,48728,2219,539 ---- 99.9%Approved—
4. To approve the adoption of the Company's 2026 Equity Incentive Plan 47,745,5628,826,70317,748 --2,819,234 84%Approved—

Source: Protagonist Therapeutics, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.

How asset managers voted at the Protagonist Therapeutics, Inc. 2025-2026 meeting

362 asset managers disclosed a vote on at least one Protagonist Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Dinesh V. Patel, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%
FOR: 48,714,702WITHHELD: 7,875,311
Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Dinesh V. Patel, Ph.D.

Protagonist Therapeutics, Inc.’s own tally for this item (“Elect Director: Dinesh V. Patel, Ph.D.”): 48,714,702 for, 7,875,311 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 104 asset managers below reported 25,050,958 for, 1,620,821 withheld, 357,599 abstained.

FOR
FOR: 25,050,958ABSTAIN: 357,599WITHHOLD: 1,620,821
Largest asset managers voting on “To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholder” at Protagonist Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,196,7750 560For
BlackRock5,991,9340 00For
Fidelity2,154,0910 00For
Invesco1,570,6870 00For
T. Rowe Price1,349,0850 00For
JANUS INVESTMENT FUND978,0110 00For
State Street773,4560 0890For
Prudential/PGIM484,6160 04,528For
Charles Schwab482,2500 00For
American Century00 0412,809Withhold
Jackson National188,3070 198,7490Mixed
Lord Abbett343,3580 00For
Voya304,4050 00For
Legg Mason235,2160 06,209For
Hartford226,2400 00For
Putnam172,6470 00For
Victory Capital5440 0161,490Withhold
Equitable146,0290 00For
DRIEHAUS MUTUAL FUNDS00 0138,752Withhold
Columbia Threadneedle133,8150 00For
JPMorgan133,3120 00For
Brighthouse107,1160 018,373Mixed
John Hancock51,4400 73,3610Mixed
TIAA118,0950 00For
AIG/SunAmerica00 0108,768Withhold

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

Elect Director: Lewis T. "Rusty" Williams, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 8 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD
FOR: 45,371,193WITHHELD: 11,218,820
Details: description as filed, official tally, votes by 104 asset managers

Description as filed by funds: To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Lewis T. "Rusty" Williams, M.D., Ph.D.

Protagonist Therapeutics, Inc.’s own tally for this item (“Elect Director: Lewis T. "Rusty" Williams, M.D., Ph.D.”): 45,371,193 for, 11,218,820 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 104 asset managers below reported 22,858,860 for, 3,225,193 withheld, 945,325 abstained.

FOR
FOR: 22,858,860ABSTAIN: 945,325WITHHOLD: 3,225,193
Largest asset managers voting on “To elect the Class I director nominees named below to hold office until the 2029 Annual Meeting of Stockholder” at Protagonist Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,196,7540 770For
BlackRock5,438,1310 553,8030Mixed
Fidelity2,154,0910 00For
Invesco1,570,6870 00For
T. Rowe Price00 01,349,085Withhold
JANUS INVESTMENT FUND978,0110 00For
State Street773,4560 0890For
Prudential/PGIM484,6160 04,528For
Charles Schwab482,2500 00For
American Century00 0412,809Withhold
Jackson National186,9520 200,1040Mixed
Lord Abbett343,3580 00For
Voya304,4050 00For
Legg Mason235,2160 06,209For
Hartford226,2400 00For
Putnam172,6470 00For
Victory Capital5440 0161,490Withhold
Equitable82,7880 063,241Mixed
DRIEHAUS MUTUAL FUNDS00 0138,752Withhold
Columbia Threadneedle133,8150 00For
JPMorgan133,3120 00For
Brighthouse94,3110 031,178Mixed
John Hancock27,4440 97,3570Mixed
TIAA00 0118,095Withhold
AIG/SunAmerica00 0108,768Withhold

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

To approve the adoption of the Company's 2026 Equity Incentive Plan

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

84% Approved · of votes cast

FOR 84%AGAINST
FOR: 47,745,562AGAINST: 8,826,703
Details: description as filed, official tally, votes by 111 asset managers

Description as filed by funds: TO APPROVE THE ADOPTION OF THE COMPANY'S 2026 EQUITY INCENTIVE PLAN.

Protagonist Therapeutics, Inc.’s own tally for this item (“4. To approve the adoption of the Company's 2026 Equity Incentive Plan”): 47,745,562 for, 8,826,703 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 84% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 105 asset managers voting on “TO APPROVE THE ADOPTION OF THE COMPANY'S 2026 EQUITY INCENTIVE PLAN.” at Protagonist Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,179,22217,609 00For
BlackRock5,991,9340 00For
Fidelity2,154,0910 00For
Invesco1,570,6870 00For
T. Rowe Price1,349,0850 00For
JANUS INVESTMENT FUND978,0110 00For
State Street772,5591,787 00For
Prudential/PGIM481,3767,768 00For
Charles Schwab482,2500 00For
American Century0412,809 00Against
Jackson National188,307198,749 00Mixed
Lord Abbett343,3580 00For
Voya0304,405 00Against
Legg Mason235,2166,209 00For
Hartford226,2400 00For
Putnam6,532172,647 00Against
Victory Capital544161,490 00Against
Equitable146,0290 00For
DRIEHAUS MUTUAL FUNDS0138,752 00Against
Columbia Threadneedle133,8150 00For
JPMorgan133,3120 00For
John Hancock51,44073,361 00Mixed
TIAA118,0950 00For
AIG/SunAmerica0108,768 00Against
QUANTITATIVE MASTER SERIES LLC94,5950 00For

Fund voting reports, all 105 managers: 24,438,127 for, 2,451,413 against, 14,349 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 6 asset managers voting on “TO APPROVE THE ADOPTION OF THE COMPANY'S 2026 EQUITY INCENTIVE PLAN.” at Protagonist Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Duquesne Family Office LLC159,7000 00For
NEXTBio Capital Management LP152,8660 00For
Vident Advisory, LLC4,6980 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC4,2920 00For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma5040 00For
Boltwood Capital Management1400 00For

Institutional-manager reports, all 6 managers: 322,200 for.

To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 53,412,559AGAINST: 3,164,702

Prior year: 94.7% for (June 20, 2025 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 362 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.

Protagonist Therapeutics, Inc.’s own tally for this item (“2. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers”): 53,412,559 for, 3,164,702 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 107 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at Protagonist Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,196,8229 00For
BlackRock5,991,9340 00For
Fidelity2,154,0910 00For
Invesco457,6681,113,019 00Mixed
T. Rowe Price1,349,0850 00For
JANUS INVESTMENT FUND978,0110 00For
State Street774,025321 00For
Prudential/PGIM489,1440 00For
Charles Schwab482,2500 00For
American Century412,8090 00For
Jackson National200,104186,952 00Mixed
Lord Abbett343,3580 00For
Voya304,4050 00For
Legg Mason241,4250 00For
Hartford226,2400 00For
Putnam179,1790 00For
Victory Capital162,0340 00For
Equitable146,0290 00For
DRIEHAUS MUTUAL FUNDS138,7520 00For
Columbia Threadneedle133,8150 00For
JPMorgan133,3120 00For
Brighthouse31,17894,311 00Mixed
John Hancock124,8010 00For
TIAA118,0950 00For
AIG/SunAmerica108,7680 00For

Fund voting reports, all 107 managers: 25,550,429 for, 1,483,388 against, 9,310 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 284 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at Protagonist Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP5,059,0530 00For
FARALLON CAPITAL MANAGEMENT, L.L.C.4,779,0800 00For
Janus Henderson3,439,8290 00For
Wellington2,703,5110 00For
BlackRock1,834,48931,019 00For
State Street1,863,089321 00For
T. Rowe Price1,749,6450 00For
GEODE CAPITAL MANAGEMENT, LLC1,679,6990 00For
Invesco30,9381,530,435 00Against
Woodline Partners LP1,219,3060 00For
ADAR1 Capital Management, LLC908,4830 00For
JENNISON ASSOCIATES LLC835,4810 00For
Fidelity666,3400 00For
Clearbridge Investments, LLC623,9010 00For
Charles Schwab553,7170 00For
Northern Trust522,7014,088 00For
PICTET ASSET MANAGEMENT SA516,3330 00For
Vanguard503,4540 00For
American Century461,1580 00For
Voya418,5890 00For
LORD, ABBETT & CO. LLC377,2360 00For
PRINCIPAL GLOBAL INVESTORS369,0140 00For
DRIEHAUS CAPITAL MANAGEMENT LLC361,1420 00For
Hood River Capital Management LLC348,1710 00For
Focus Partners Wealth334,341164 00For

Institutional-manager reports, all 284 managers: 38,002,679 for, 2,644,148 against, 139 abstained, 3,689 not voted. Showing the 25 largest; every one is in the interactive database (link above).

To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 59,371,487AGAINST: 28,221

Prior year: 99.9% for (June 20, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 107 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

Protagonist Therapeutics, Inc.’s own tally for this item (“3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026”): 59,371,487 for, 28,221 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 107 asset managers below reported 27,009,492 for, 24,325 against, 9,310 abstained.

FOR
FOR: 27,009,492AGAINST: 24,325ABSTAIN: 9,310
Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FO” at Protagonist Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard8,196,8310 00For
BlackRock5,991,9340 00For
Fidelity2,154,0910 00For
Invesco1,570,6870 00For
T. Rowe Price1,349,0850 00For
JANUS INVESTMENT FUND978,0110 00For
State Street774,3460 00For
Prudential/PGIM489,1440 00For
Charles Schwab482,2500 00For
American Century412,8090 00For
Jackson National387,0560 00For
Lord Abbett343,3580 00For
Voya304,4050 00For
Legg Mason241,4250 00For
Hartford226,2400 00For
Putnam179,1790 00For
Victory Capital162,0340 00For
Equitable146,0290 00For
DRIEHAUS MUTUAL FUNDS138,7520 00For
Columbia Threadneedle133,8150 00For
JPMorgan133,3120 00For
Brighthouse125,4890 00For
John Hancock124,8010 00For
TIAA118,0950 00For
AIG/SunAmerica108,7680 00For

Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).

Largest Protagonist Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 64,227,057 shares outstanding at the time of that meeting.

Fund voting reports: top Protagonist Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 12.76%
2BlackRock 9.33%
3Fidelity 3.35%
4Invesco 2.45%
5T. Rowe Price 2.10%
6JANUS INVESTMENT FUND 1.52%
7State Street 1.21%
8Prudential/PGIM 0.76%
9Charles Schwab 0.75%
10American Century 0.64%
Institutional-manager reports: top Protagonist Therapeutics, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 7.88%
2FARALLON CAPITAL MANAGEMENT, L.L.C. 7.44%
3Janus Henderson 5.36%
4Wellington 4.21%
5BlackRock 2.90%
6State Street 2.90%
7T. Rowe Price 2.72%
8GEODE CAPITAL MANAGEMENT, LLC 2.62%
9Invesco 2.43%
10Woodline Partners LP 1.90%

Reported Protagonist Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Protagonist Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock9,779,369 15.23%Form 13F, quarter ended March 31, 2026
Entities affiliated with BlackRock, Inc.8,575,669 13.35%Proxy statement (DEF 14A), table as of March 13, 2026
Farallon Capital Management, L.L.C.6,433,119 10.02%Schedule 13G, filed August 13, 2026
Entities affiliated with Farallon Partners, L.L.C.6,401,006 9.97%Proxy statement (DEF 14A), table as of March 13, 2026
Entities affiliated with The Vanguard Group5,413,690 8.43%Proxy statement (DEF 14A), table as of March 13, 2026
Vanguard Group5,413,690 8.43%Form 13F, quarter ended March 31, 2026
Entities affiliated with RTW Investments, L.P.5,059,053 7.88%Proxy statement (DEF 14A), table as of March 13, 2026
RTW Investments, LP5,059,053 7.88%Schedule 13G, filed February 17, 2026
Wellington Management3,599,644 5.60%Form 13F, quarter ended March 31, 2026
Vanguard Portfolio Management3,533,015 5.50%Schedule 13G, filed April 29, 2026

Percentages above are of 64,227,057 shares outstanding, as reported by Protagonist Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Protagonist Therapeutics, Inc.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 362 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,507 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — Protagonist Therapeutics, Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Protagonist Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Protagonist Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Protagonist Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Protagonist Therapeutics (PTGX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/protagonist-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.